Kazunari Tateishi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9403424/publications.pdf

Version: 2024-02-01

	1162889	1199470
189	8	12
citations	h-index	g-index
1.0	1.0	000
18	18	208
docs citations	times ranked	citing authors
	citations 18	189 8 citations h-index 18 18

#	Article	IF	CITATIONS
1	Lung immune prognostic index as a prognostic factor in patients with small cell lung cancer. Thoracic Cancer, 2020, 11, 1578-1586.	0.8	22
2	Clinical utility of the Câ€reactive protein:albumin ratio in nonâ€small cell lung cancer patients treated with nivolumab. Thoracic Cancer, 2021, 12, 603-612.	0.8	20
3	Prognostic Factors and Efficacy of First-Line Chemotherapy in Patients with Advanced Thymic Carcinoma: A Retrospective Analysis of 286 Patients from NEJ023 Study. Oncologist, 2018, 23, 1210-1217.	1.9	19
4	Prognostic value of the geriatric nutritional risk index among patients with previously treated advanced nonâ€small cell lung cancer who subsequently underwent immunotherapy. Thoracic Cancer, 2021, 12, 1366-1372.	0.8	19
5	Modified Glasgow Prognostic Score as a Prognostic Factor in Patients with Extensive Disease-Small-Cell Lung Cancer: A Retrospective Study in a Single Institute. Chemotherapy, 2019, 64, 129-137.	0.8	18
6	Clinical Outcomes of Second-Line Chemotherapy in Patients with Previously Treated Advanced Thymic Carcinoma: A Retrospective Analysis of 191 Patients from the NEJ023 Study. Oncologist, 2020, 25, e668-e674.	1.9	15
7	The Role of Immune-Related Adverse Events in Prognosis and Efficacy Prediction for Patients with Non-Small Cell Lung Cancer Treated with Immunotherapy: A Retrospective Clinical Analysis. Oncology, 2021, 99, 271-279.	0.9	11
8	Two patients with TAFRO syndrome exhibiting strikingly similar anterior mediastinal lesions with predominantly fat attenuation on chest computed tomography. Respiratory Investigation, 2017, 55, 176-180.	0.9	9
9	Predictive value of <scp>postâ€treatment Câ€reactive proteinâ€toâ€albumin</scp> ratio in locally advanced <scp>non–small</scp> cell lung cancer patients receiving durvalumab after chemoradiotherapy. Thoracic Cancer, 2022, 13, 2031-2040.	0.8	8
10	Clinical analysis of patients treated with afatinib for advanced non-small cell lung cancer: A Nagano Lung Cancer Research Group observational study. Respiratory Investigation, 2016, 54, 462-467.	0.9	7
11	Prognostic factors for patients with metastatic or recurrent thymic carcinoma receiving palliative-intent chemotherapy. Lung Cancer, 2020, 148, 122-128.	0.9	7
12	Successful recovery from critical COVID-19 pneumonia with extracorporeal membrane oxygenation: A case report. Respiratory Medicine Case Reports, 2020, 30, 101113.	0.2	6
13	Predictive Factors Correlated with the Development of Immune-Related Adverse Events in Patients with Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors. Cancer Management and Research, 2022, Volume 14, 427-435.	0.9	6
14	Clinical analysis ofEGFRâ€positive nonâ€small cell lung cancer patients treated with firstâ€line afatinib: A Nagano Lung Cancer Research Group. Thoracic Cancer, 2019, 10, 1078-1085.	0.8	5
15	Prognostic implication of erector spinae muscles in nonâ€smallâ€cell lung cancer patients treated with immunoâ€oncology combinatorial chemotherapy. Thoracic Cancer, 2021, 12, 2857-2864.	0.8	5
16	Pembrolizumab-Induced Adrenal Insufficiency in Patients with Untreated Advanced Non-Small Cell Lung Cancer: A Case Series. Case Reports in Oncology, 2022, 14, 1561-1566.	0.3	5
17	The efficacy of amrubicin thirdâ€line chemotherapy in patients with relapsed extensiveâ€disease smallâ€cell lung cancer: A retrospective and historical study in a single institute. Thoracic Cancer, 2019, 10, 1805-1811.	0.8	4
18	Association of lung immune prognostic index with survival outcome in advanced thymic carcinoma patients treated with palliative intent chemotherapy. Thoracic Cancer, 2022, 13, 1006-1013.	0.8	3